Fresenius, WuXi Enter Development Agreement To Expand Biosimilars Pipeline
The deal gives Fresenius access to 37 biosimilar candidates and could expand its portfolio from 29 to 66 molecules, the company said.
- On Monday, Fresenius SE & Co. KGaA signed an exclusive development agreement with WuXi Biologics, granting the German healthcare group access to up to 37 identified biosimilar candidates over the next decade.
- This partnership provides a scalable pathway for Fresenius to expand its biosimilar portfolio from 29 molecules to up to 66, targeting markets representing more than €370 billion in originator list-price-based sales.
- "We are doubling down on our Biopharma business," CEO Michael Sen said, noting the deal complements Fresenius' full ownership of mAbxience acquired in October 2026.
- Fresenius confirmed its 2026 financial targets while expecting to raise long-term Biopharma ambitions significantly, with WuXi compensated on a fee-for-service basis as programs advance.
- Development programs will be selected based on market attractiveness, development risk, and expected returns, positioning Fresenius to fuel long-term Biopharma growth well beyond 2030.
14 Articles
14 Articles
From 2028, the patents of many biotech drugs will expire. Then, the hour of the cheaper counterfeiter products will come to an end. The market is worth billions. Fresenius is now positioning itself with a further acquisition
Zeit Online
stern.de
Fresenius signs biosimilars pipeline agreement with WuXi Biologics - Regional Media News
Nov 2 (Reuters) - Fresenius has signed a development agreement for biosimilar drugs with China's WuXi Biologics, the German healthcare group said on Monday. The agreement gives Fresenius exclusive access to up to 37 identified biosimilar candidates over the next decade, addressing more than €370 [...]
Fresenius, WuXi Enter Development Agreement To Expand Biosimilars Pipeline
Fresenius SE & Co. KGaA has entered an exclusive development agreement with WuXi Biologics (2269.HK), which provides Fresenius access to up to 37 identified biosimilar candidates over the next decade. The company said the agreement provides access to a scalable pathway to increase the portfolio from 29 marketed and pipeline molecules to up to 66 molecules, addressing more than 370 billion euros in originator list-price-based-sales. Fresenius wil…
Coverage Details
Bias Distribution
- 56% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
